SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hikal touches roof on developing Favipiravir Active Pharmaceutical ingredient

15 May 2020 Evaluate
Hikal is currently trading at its upper limit of Rs. 114.95, up by 5.45 points or 4.98% from its previous closing of Rs. 109.50 on the BSE.

The scrip opened at Rs. 114.00 and has touched a high and low of Rs. 114.95 and Rs. 110.00 respectively. So far 31324 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 180.25 on 27-May-2019 and a 52 week low of Rs. 57.00 on 25-Mar-2020.

Last one week high and low of the scrip stood at Rs. 114.95 and Rs. 97.15 respectively. The current market cap of the company is Rs. 1417.34 crore.

The promoters holding in the company stood at 68.77%, while Institutions and Non-Institutions held 6.80% and 24.43% respectively.

Hikal has successfully developed Favipiravir Active Pharmaceutical ingredient (API) and its intermediates. Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co., Japan, a subsidiary of Fujifilm Corporation. Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. It is in various stages of clinical trials in many countries as an experimental treatment of COVID-19.

The company is in discussion with potential partners to supply the API and its intermediates.

Hikal has developed this API in a record amount of time to make the product available for treatment of COVID-19. This demonstrates Hikal's commitment to support in the fight against COVID-19 virus and to provide high quality medicines to its customers globally.

Hikal is a leading manufacturer and supplier of API's and intermediates globally.

Hikal Share Price

192.15 3.60 (1.91%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×